DOCSLIB.ORG

Diol in Urine of University Students

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Utah State University DigitalCommons@USU All Graduate Theses and Dissertations Graduate Studies 5-1966 Cholesterol Levels in Serum and 5β – Pregnane – 3α,20α - diol in Urine of University Students Gertrude Kuei-Shu Chiang Utah State University Follow this and additional works at: https://digitalcommons.usu.edu/etd Part of the Food Science Commons Recommended Citation Chiang, Gertrude Kuei-Shu, "Cholesterol Levels in Serum and 5β – Pregnane – 3α,20α - diol in Urine of University Students" (1966). All Graduate Theses and Dissertations. 4820. https://digitalcommons.usu.edu/etd/4820 This Thesis is brought to you for free and open access by the Graduate Studies at DigitalCommons@USU. It has been accepted for inclusion in All Graduate Theses and Dissertations by an authorized administrator of DigitalCommons@USU. For more information, please contact [email protected]. CHOLESTEROL LEVELS IN SERUM AND 5� -PREGNANE-3D( ,20o(.-DIOL IN URINE OF UNIVERSITY STUDENTS by Gertrude Kuei-Shu Chiang A thesis submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Nutrition and Biochemistry UTAH STATE UNIVERSITY� Logan, Utah 1966 TABLE OF CONTENTS INTRODUCTION 1 REVIEW OF LITERATURE 4 Physiological effects of progesterone 4 Source and metabolism 4 Function in the body and its excretion 6 Analytical method of urinary pregnanediol The relationships of serum cholesterol and coronary atherosclerosis 8 The influence of the sex hormones on the circulating lipids . 13 Serum cholesterol levels and eating frequency 14 Analytical method of serum cholesterol 16 METHOD AND PROCEDURE 18 Experimental design 18 Collection and storage of urine specimens 20 Collection 20 Storage . 22 Analysis of ur inary Sft-pregnane -~, 2~-diol 22 Method 22 Equipment 22 Reagents 23 Procedure 23 Hydrolysis 24 Extraction 24 llage Washing and drying 24 Preparing the glass plates 25 Chromatography 26 Spectrophotometry 28 Calculation 29 Recovery 29 Preparation of serum samples 29 Analysis of serum cholesterol 31 Method 32 Equipment 32 Reagents 33 Procedure 34 Extraction and sampling 34 Precipitation of total cholesterol 34 Precipitation of free cholesterol . 35 Washing of the cholesterol digitonide precipitates 35 Color development 36 Calculation 37 Recovery 37 RESULTS AND DISCUSSION 39 Urinary pregnanediol levels 39 Effect of menstrual cycle 43 Effect of two meals versus three meals per day 43 Serum cholesterol levels 55 Effect of menstrual cycle 63 Page Effect of two meals versus three meals per day 63 Effect of dietary factors 66 Relationships between serum choles terol and degra­ dation products of androgens and progesterone 72 COMMENTS AND CONCLUSIONS 76 SUMMARY 78 LITERATURE CITED 80 APPENDIX 84 LIST OF TABLES Table Page 1. Experimental design 19 2. Mean age, weight, and height of subjects 21 3. Recovery test of urinary pregnanediol 30 4. Recovery test of serum cholesterol 38 5. Summary of mean squares obtained by analysis of variance of data on urinary pregnanediol 40 6. Mean values of pregnanediol in urine of subjects consuming two meals and three meals per day 41 7. Urinary pregnanediol values of normal humans as reported in the literature . 42 8. Summary of mean squares obtained by analysis of variance of data on serum cholesterol of male and female subjects 56 9. Summary of mean squares obtained by analysis of variance of data on serum cholesterol of female subjects 57 10. Percentage distribution of nine subjects within various ranges of serum total cholesterol values 58 11. Mean serum cholesterol concentrat ion by sex and meals 12. Mean values of total and free cholesterol in serum of subjects consuming two and three meals per day 61 13. The range of serum total cholesterol values for individual subjects by number of meals . 62 14. The effect of menstrual cycle on the concentration of the serum cholesterol 15. Mean food intake of the subjects 70 16. The relationship between serum cholesterol and urinary neutral 17-ketosteroid, and pregnanediol by sex 75 Table Page 17. Urinary 5$ -pregnane3oL,20ol-diol values for individual subjects consuming two meals and three meals per day 18. Urinary pregnanediol excretion values for the individual subjects consuming two meals and three meals per day by day of menstrual cycle 19. Urinary pregnanediol excretion values for the individual subjects by day of menstrual cycle 87 20. Serum total cholesterol values for individual subjects eating two meals and three meals per day 88 21. Serum free cholesterol values for individual subjects consuming two meals and three meals per day LIST OF FIGURES Figure Page 1. Biosynthesis and metabolism of progesterone 2. The effect of day of menstrual cycle on excretion values of pregnanediol and the levels of serum cholesterol 44 3. The effect of day of menstrual cycle on mean excretion values of pregnanediol of 5 subjects 44A 4. Urinary pregnanediol excretion values and serum cholesterol levels by day of menstrual cycle for subject S.R. 45 5. Urinary pregnanediol excretion values and serum cholesterol levels by day of menstrual cycle for subject T.D. 46 6. Urinary pregnanediol excretion values and serum cholesterol levels by day of menstrual cycle for subject J .A. 47 7. Urinary pregnanediol excretion values and serum cholesterol levels by day of menstrual cycle for subject B.N. 48 8. Urinary pregnanediol excretion values and serum cholesterol levels by day of menstrual cycle for subject M.J. 49 9. The effect of number of meals on mean excretion values of urinary pregnanediol for male subjects 50 10. The effect of number of meals by day of test period on pregnanediol excretion values for male subjects 51 11. The effect of number of meals on mean excretion values of urinary pregnanediol for female subjects 53 12. The effect of number of meals by day of menstrual cycle on pregnanediol excretion values 54 13. Mean total cholesterol values for men with or with- out lunch by days of study . 65 Figure Page 14. Mean total cholesterol values for women with or with­ out lunch by days of menstrual cycle 67 15. The effect of number of meals by days of study on total serum cholesterol values fo r men 68 16. The effect of number of meals by days of menstrual cycle on total serum cholesterol values 69 17. Mean serum cholesterol and urinary neutral 17- ketosteroid and pregnanediol values by days of study for men 73 18. Mean serum cholesterol and urinary neutral 17- ketos teroid and pregnanediol values by days of menstrual cycle for women ACKNOWLEDGEMENTS The author wishes to express her gratitude to Dr. Ethelwyn B. Wilcox for her untiring efforts in initiating this problem and in making suggestions and counseling throughout this study. Appreciation is also expressed to Dr. Joseph C. Street, Mrs. Grace J. Smith, and Dr. Elveda Smith for their special assistance and suggestions. Thanks are given to Dr. Donald V. Sisson for his help with the statistical analysis. This study was part of the Western Regional Research Project on Biological Interrelationships in Lipid Metabolism of Importance to Man. It was supported in part by W-44 funds obtained under the Research and Marketing Act. Acknowledgement is given to all others who gave their assistance and encouragement and thanks to those persons who acted as experimental subjects. INTRODUCTION Since there is a high incidence of coronary heart disease in humans of middle-age and older in the United States, and the mortality of this disease is still increasing, a great deal of research has been done in this field. Although many theories have been formulated con­ cerning the cause of atherosclerosis, it is a very complex disease, and appears to be influenced by many factors. Disturbed lipid meta­ bolism is widely believed to be involved in the development of the vascular lesions found in arteriosclerosis, although the nature and origin of the disturbance is unknown. The mechanism for the elevation of serum cholesterol and triglyceride levels is not known; but sex hormones and dietary constituents are believed to be among the factors involved. The concept that atherosclerosis is a metabolic disorder involving lipids and lipoproteins has stimulated extensive investigation of the endocrine influences on circulating lipids and on lipid metabolism. The results have consistently indicated that estrogens decrease cir­ culating cholesterol and prevent cholesterol induced coronary atheros­ clerosis, while androgen administration tends to increase circulating cholesterol . There are relative few studies of the effect of other sex hormones, such as progesterone. There is only limited information on the relationship between the level of progesterone and the concentra­ tion of serum cholesterol in healthy adults while living under ordinary living conditions. Further work with more subjects is desirable. Since the discovery by Marrian and co-workers (1929) of S~preg­ nane-3ol,200l-diol in urine of pregnant woman and the perfection of a quantitative method for its determination by Venning (1937), this compound has received wide attention because of its close relation to the meta- holism of the corpus luteum hormone, progesterone. Pregnanediol is the major end product of progesterone catabolism and its estimation provides a useful index of luteal function. Progesterone has been isolated from three mammalian tissue sources, the corpus luteum, the adrenal, and the placenta. The function of progesterone i s to promote the prolifer­ ation of uterine mucosa and thus to prepare this tissue to receive the fertilized ovum. Cholesterol, literally meaning bile solid-alcohol, derives its name from the fact that it was first isolated from human gallstones, of which it is generally the chief component. The amount of chole­ sterol in animal tissues varies widely. It is particularly abundant in brain and nerve tissue, adrenal glands , and egg yolk. It had been shown that the administration of deuterium-labeled cholesterol to a pregnant woman gave rise t o labeled pregnanediol in the urine.
Recommended publications
  • Seco-Steroids C07C)

    Seco-Steroids C07C)

    CPC - C07J - 2021.08 C07J STEROIDS (seco-steroids C07C) Definition statement This place covers: Compounds containing a cyclopenta[a]hydrophenanthrene skeleton (see below) or a ring structure derived therefrom: • by contraction or expansion of one ring by one or two atoms; • by contraction or expansion of two rings each by one atom; • by contraction of one ring by one atom and expansion of one ring by one atom; • by substitution of one or two carbon atoms of the cyclopenta[a]hydrophenanthrene skeleton, which are not shared by rings, by hetero atoms, in combination with the above defined contraction or expansion or not, or; • by condensation with carbocyclic or heterocyclic rings in combination with one or more of the foregoing alterations or not. Preparation of steroids including purification, separation, stabilisation or use of additives unless provided for elsewhere, as specified below. Treatment and modification of steroids provided that • the treatment is not provided for elsewhere and • the resultant product is a compound under the subclass definition. Relationships with other classification places In class C07, in the absence of an indication to the contrary, a compound is classified in the last appropriate place, i.e. in the last appropriate subclass. For example cyclopenta [a] hydrophenantrenes are classified in subclass C07J as steroids and not in subclasses C07C or C07D as carbocyclic or heterocyclic compounds. Subclass C07J is a function-oriented entry for the compounds themselves and does not cover the application or use of the compounds under the subclass definition. For classifying such information other entries in the IPC exist, for example: Subclass A01N: Preservation of bodies of humans or animals or plants or parts thereof; biocides, e.g.
  • Research Collection

    Research Collection

    Research Collection Doctoral Thesis Some reactions in the D-ring of the steroids Author(s): Boyce, Sam Framroze Publication Date: 1958 Permanent Link: https://doi.org/10.3929/ethz-a-000089222 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library Prom. Nr. 2111 SOME REACTIONS IN THE D-RING 0! THE STEROIDS Thesis presented to The Swiss Federal Institute of Technology Zurich for the Degree of Doctor of Technical Science by SAM FRAMROZE BOYCE Indian Citizen Accepted on the recommendation of Prof. Dr. L. Ruzicka Priv. Doz. Dr. H. Heusser The Commercial Printing Press Private Ltd., Bombay 1958 TO THE MEMORY OF MY DEAR PARENTS ACKNOWLEDGEMENTS For giving me the opportunity to carry out this work, for his encouragement and keen interest during its progress, I here express my deep gratitude to Prof. L. Ruzicka. I am also indebted to Prof. L. Ruzicka and Prof. PI. A. Plattner for guidance of this work. My sincere thanks are also due to P. D. Dr. H. Heussor for his continued co-operation and helpful suggestions during the course of this work. To Prof. V. Prelog, I am obliged for the valuable discussions and critical comments. Finally, I am indebted to Prof. M. Giinthard for the infra-red spectra and to Mr. W. Manser for the micro-analysis. m CONTENTS GENERAL INTRODUCTION 1 Pabt I REARRANGEMENT OF a-HALOGENO-20-KETOSTEROIDS Theoretical Part 3 Experimental Part 10 Pabt Ha BASE CATALYSED REACTIONS WITH A16-3 jS-ACETOXY- 14,15 0-EPOXY-5-ALLOETIOCHOLENIC ACID METHYL ESTER Theoretical Part 18 Experimental Part 27 Pabt lib BASE AND ACID CATALYSED REACTIONS WITH A16-3j3- ACETOXY-14,15/3-EPOXY-20-KETO-5-ALLOPREGNENE Theoretical Part ..
  • Proceedings of the Thirtieth Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N

    Proceedings of the Thirtieth Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N

    PROCEEDINGS OF THE THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1938 J Clin Invest. 1938;17(4):501-537. https://doi.org/10.1172/JCI100977. Research Article Find the latest version: https://jci.me/100977/pdf PROCEEDINGS OF THE THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1938 READ BEFORE THE SCIENTIFIC SESSION The Successful Treatment of Pernicious Anemia by in powdered form hemostasis was readily obtained in Means of Non-Autolyzed Yeast. By MAXWELL M. hemorrhages following nine dental extractions and three WINTROBE, Baltimore, Md. external wounds in five hemophilic subjects. When ap- It has been the general opinion that yeast, if it pos- plied in liquid form as other hemostatics are usually em- sesses any antianemic potency whatever, is effective only 1 loyed the results were unsatisfactory. Since the co- after autolysis and then only by virtue of its content of agulation time of the circulating blood was unchanged the "extrinsic factor." The observations reported contradict effectiveness of powdered beef globulin substance when this view and indicate that dehydrated yeast which has locally applied to a bleeding wound in hemophilia is not been subjected to autolysis, contains an antiper- attributed to the rapid formation of a firm fibrin clot. nicious anemia substance. Yeast obtained from two dif- The failure of liquid preparations may be due to the ferent sources was effective in the treatment of classical inability to maintain a sufficient concentration of the cases of pernicious anemia.
  • University Microfilms, Inc., Ann Arbor, Michigan ADRENOCORTICAL STEROID PROFILE IN

    University Microfilms, Inc., Ann Arbor, Michigan ADRENOCORTICAL STEROID PROFILE IN

    This dissertation has been Mic 61-2820 microfilmed exactly as received BESCH, Paige Keith. ADRENOCORTICAL STEROID PROFILE IN THE HYPERTENSIVE DOG. The Ohio State University, Ph.D., 1961 Chemistry, biological University Microfilms, Inc., Ann Arbor, Michigan ADRENOCORTICAL STEROID PROFILE IN THE HYPERTENSIVE DOG DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of the Ohio State University By Paige Keith Besch, B. S., M. S. The Ohio State University 1961 Approved by Katharine A. Brownell Department of Physiology DEDICATION This work is dedicated to my wife, Dr. Norma F. Besch. After having completed her graduate training, she was once again subjected to almost social isolation by the number of hours I spent away from home. It is with sincerest appreciation for her continual encouragement that I dedi­ cate this to her. ACKNOWLEDGMENTS I wish to acknowledge the assistance and encourage­ ment of my Professor, Doctor Katharine A. Brownell. Equally important to the development of this project are the experience and information obtained through the association with Doctor Frank A. Hartman, who over the years has, along with Doctor Brownell, devoted his life to the development of many of the techniques used in this study. It is also with extreme sincerity that I wish to ac­ knowledge the assistance of Mr. David J. Watson. He has never complained when asked to work long hours at night or weekends. Our association has been a fruitful one. I also wish to acknowledge the encouragement of my former Professor, employer and good friend, Doctor Joseph W.
  • US2940991.Pdf

    US2940991.Pdf

    2,940,991 Paterated Jj Line 4, 1960 United States Patent Office 2 provide easy access to other biologically active steroid compounds. 2,940,991 These and other objects of this invention will become apparent on reading the following description in con METHOD OF EPIMERIZING 11-BROMO junction with the drawings in which: STERODS Figure 1 is a schematic representation of the process Percy L. Juliana, Oak Park, and Arthur Magnani, Wi in accordance with this invention. w X mette, Ill., assignors to The Julian Laboratories, ne, With respect to the following description, it is desired Frankin Park, I., a corporation of Illinois to point out that reduction providing an OH group in the O 12-position results in a mixture of compounds, some Filed Mar. 1, 1957, Ser. No. 643,353 having the OH bonded by a bond in the or position and 7 Claims. (C. 260-397.45) some by a bond in the 6 position. In the starting mate rial triols either the 12c ol or 126 ol compounds or a Rixture thereof may be employed. The structural formu This invention relates to novel steroid compounds and 15 las herein and in the claims are intended to cover both to processes for their preparation. The compounds of the 12c, ols and 12p ols where discussed and/or claimed. this invention are particularly useful as intermediates in It is also desired to point out that the steroid com the preparation of cortical hormones which have useful pounds discussed and claimed exist in either the 3ox,56 therapeutic activity.
  • Nomenclature of Steroids

    Nomenclature of Steroids

    Pure&App/. Chern.,Vol. 61, No. 10, pp. 1783-1822,1989. Printed in Great Britain. @ 1989 IUPAC INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY and INTERNATIONAL UNION OF BIOCHEMISTRY JOINT COMMISSION ON BIOCHEMICAL NOMENCLATURE* NOMENCLATURE OF STEROIDS (Recommendations 1989) Prepared for publication by G. P. MOSS Queen Mary College, Mile End Road, London El 4NS, UK *Membership of the Commission (JCBN) during 1987-89 is as follows: Chairman: J. F. G. Vliegenthart (Netherlands); Secretary: A. Cornish-Bowden (UK); Members: J. R. Bull (RSA); M. A. Chester (Sweden); C. LiCbecq (Belgium, representing the IUB Committee of Editors of Biochemical Journals); J. Reedijk (Netherlands); P. Venetianer (Hungary); Associate Members: G. P. Moss (UK); J. C. Rigg (Netherlands). Additional contributors to the formulation of these recommendations: Nomenclature Committee of ZUB(NC-ZUB) (those additional to JCBN): H. Bielka (GDR); C. R. Cantor (USA); H. B. F. Dixon (UK); P. Karlson (FRG); K. L. Loening (USA); W. Saenger (FRG); N. Sharon (Israel); E. J. van Lenten (USA); S. F. Velick (USA); E. C. Webb (Australia). Membership of Expert Panel: P. Karlson (FRG, Convener); J. R. Bull (RSA); K. Engel (FRG); J. Fried (USA); H. W. Kircher (USA); K. L. Loening (USA); G. P. Moss (UK); G. Popjiik (USA); M. R. Uskokovic (USA). Correspondence on these recommendations should be addressed to Dr. G. P. Moss at the above address or to any member of the Commission. Republication of this report is permitted without the need for formal IUPAC permission on condition that an acknowledgement, with full reference together with IUPAC copyright symbol (01989 IUPAC), is printed.
  • The Use of Altrenogest to Control Reproductive Function in Beef Cattle" (2004)

    The Use of Altrenogest to Control Reproductive Function in Beef Cattle" (2004)

    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2004 The seu of altrenogest to control reproductive function in beef cattle Clarence Edward Ferguson Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Animal Sciences Commons Recommended Citation Ferguson, Clarence Edward, "The use of altrenogest to control reproductive function in beef cattle" (2004). LSU Doctoral Dissertations. 3957. https://digitalcommons.lsu.edu/gradschool_dissertations/3957 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. THE USE OF ALTRENOGEST TO CONTROL REPRODUCTIVE FUNCTION IN BEEF CATTLE A Dissertation Submitted to the Graduate Faculty of Louisiana State University and Agricultural and Mechanical College In partial fulfillment of the Requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Animal and Dairy Sciences by Clarence Edward Ferguson B.S., McNeese State University, 1996 M.S. Stephen F. Austin State University, 1999 M.N.A.S., Southwest Missouri State University, 2000 December 2004 ACKNOWLEDGEMENTS The author would like to convey his sincere gratitude to his major professor, Dr. Robert A. Godke for his direction, patience, and commitment to train him as a research scientist. The author believes that the training he received in Dr. Godke’s Program has been and will continue to be an invaluable experience that will aid him in overcoming obstacles later in life.
  • Control of Steroid, Heme, and Carcinogen Metabolism by Nuclear Pregnane X Receptor and Constitutive Androstane Receptor

    Control of Steroid, Heme, and Carcinogen Metabolism by Nuclear Pregnane X Receptor and Constitutive Androstane Receptor

    Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor Wen Xie*†‡, Mei-Fei Yeuh‡§, Anna Radominska-Pandya¶, Simrat P. S. Saini*, Yoichi Negishi*, Bobbie Sue Bottroff†, Geraldine Y. Cabrera†, Robert H. Tukey§, and Ronald M. Evans†ʈ *Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213; †Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037; §Laboratory of Environmental Toxicology, Departments of Chemistry, and Biochemistry and Pharmacology, University of California at San Diego, La Jolla, CA 92093; and ¶Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 Contributed by Ronald M. Evans, December 31, 2002 Through a multiplex promoter spanning 218 kb, the phase II UDP- ogens, estrogen, and thyroxin metabolism. Moreover, activation of glucuronosyltransferase 1A (UGT1) gene encodes at least eight dif- PXR in transgenic mice is sufficient to increase levels of UGT ferently regulated mRNAs whose protein products function as the expression and activity, as well as bilirubin and steroid clearance. principal means to eliminate a vast array of steroids, heme metabo- lites, environmental toxins, and drugs. The orphan nuclear receptors Materials and Methods pregnane X receptor (PXR) and constitutive androstane receptor Animals. The generation of VP-hPXR, hPXR (previously known as (CAR) were originally identified as sensors able to respond to numer- VPSXR and SXR) transgenic mice and PXR null mice has been ous environmentally derived foreign compounds (xenobiotics) to described (8). promote detoxification by phase I cytochrome P450 genes. In this report, we show that both receptors can induce specific UGT1A UGT1A1 Promoter Cloning and Site-Directed Mutagenesis.
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al

    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
  • Medical Treatment of Hirsutism in Women F

    Medical Treatment of Hirsutism in Women F

    2530 Current Medicinal Chemistry, 2010, 17, 2530-2538 Medical Treatment of Hirsutism in Women F. Lumachi*,1 and S.M.M. Basso2 1Department of Surgical and Gastroenterological Sciences; 21st School of General Surgery, University of Padua, School of Medicine, 35128 Padova, Italy Abstract: Hirsutism is the presence of excess hair growth in women in the typical male hair growth areas, thereby reflect- ing a deviation from the normal female hair pattern. It affects from 5% to 10% of women, depending on age, menopausal status and ethnic background. The presence of hirsutism is very distressing for women, and subsequently may have a negative impact on their psychosocial life. In the treatment of hirsutism several options are now available, including pharmacologic regimens and cosmetic measures. Both the hormonal profile of the patient and her expectations and prefer- ences should guide the therapeutic approach. The aims of the medical therapy are suppression of excessive androgen pro- duction, inhibition of peripheral action of androgens, and treatment of patients at risk for metabolic disorders or reproduc- tive cancers. For other diseases related to endocrine abnormalities, such as thyroid disorders or Cushing’s syndrome, spe- cific treatment is mandatory. After an ineffective local approach by direct hair removal, a pharmacological treatment should be suggested, using estrogen and progestin combinations, antiandrogens (i.e. cyproterone acetate, spironolactone) or both as a first line. Finasteride, gonadotropin-releasing hormone agonists, and glucocorticoids should be used in se- lected cases. Adequate contraception is also recommended if antiandrogens are used. Unfortunately, since systemic ther- apy reduces hair growth in less than 50% of cases, hirsute women frequently require cosmetic measures.
  • UNITED STATES PATENT OFFICE 2,231,017 ALLO-PREGNANE COMPOUNDS and METH OD of OBTAINING the SAME Russell Earl Marker, State

    UNITED STATES PATENT OFFICE 2,231,017 ALLO-PREGNANE COMPOUNDS and METH OD of OBTAINING the SAME Russell Earl Marker, State

    Patented Feb. 11, 1941 2,231,017 UNITED STATES PATENT OFFICE 2,231,017 ALLO-PREGNANE COMPOUNDS AND METH OD OF OBTAINING THE SAME Russell Earl Marker, State. College, Pa., assignor to Parke, Davis & Company, Detroit, Mich., a corporation of Michigan No Drawing. Application March 12, 1937, Serial No. 130,582 6 Claims. (CI. 260-397) The invention relates to a new keto-alcohol of with a ketone reagent capable of reacting with the sterol series, and particularly to epi-allo the epi-allo-pregnane-ol- (3)-one- (20) but not pregnanol- (3)-One- (20) and its isolation from with the non-ketonic alcohols. mixtures with other sterol derivatives of a non 7. Separating the reaction product of step (6) 5 ketonic nature. from non-ketonic alcohols, and, It is known that the two non-ketonic alcohols 8. Decomposing the reaction product to obtain having a cyclopentano-10,13-dimethyl polyhy epi-allo-pregnane-ol- (3) -one- (20), which can drophenanthrene nucleus, pregnanediol and allo be readily separated by means of Organic Sol pregnanediol, belonging to the pregnane or pro vents from the decomposition products of this O gesterOne chemical group, may be isolated from Step. O the neutral or alcoholic fraction of human preg . The above series of eight steps is of Special nancy urine. However, no compounds of a keton value when the original mixture to be treated ic nature have been heretofore isolated from is a neutral carbinol fraction from human preg these or other like mixtures. nancy urine. In step (6) above the use of a It is an object of the invention to separate hydrazine compound capable of forming a and isolate the new ketonic alcohol, epi-allo water-soluble hydrazine derivative With the epi 5 pregnanol- (3)-One- (20), from its mixtures with allo-pregnanol- (3)-one- (20) is preferred as a pregnanediol and allo-pregnanediol or other like ketone reagent.
  • Steroid Mo~~~~Roa~~At~

    Steroid Mo~~~~Roa~~At~

    195 STEROID MO~~~~ROA~~AT~. P~S~~A~H~~~ CHARACTERISTICS AND USE IN GAS-LIQWID CRROMATOGRU'HP, B,J* van der Roles, D, Green and J,H* van der ma@ Departments of Obstetrics and Gynecology and Analytic&i!. Chemistry, State University, Utreeht, The Rstherlands. Received May 4, 1965 Synthesis and physical-chemical characteristics (melting points, infrared-, visibIls-and ultraviolet spectra, paper-, tbin-layer- and gas-liquid chromatographicbehaviour) of mono- chloroacetate derivatives of steroids representing the andros- tans-, pregnane-, estrane- and cholestane series are described, The usefulness of these derivatives in gas-liquid chromatogra- phy isdemonstrated. Through their strong electron absorbing properties the quantitatfon of nanogram amounts of these deri- vatives by electron capture detection is possible. shortly following the preliminary introduction of the electron capture detector in gas-liquid chromatography'I, the extreme sensitivity of this detector for chlorinated cOmpOU2Xds was used in the field of pesticides21 v The general observation that introduction of halide atoms in non-electron absorbing compounds might produce positive centers for electron attaoh- 4) ment3~, prompted ~~~~ AND LIPSKY to prepare a series of cholesteryl-haloacetatos5', They demonstrated, that the electron capture detector was far more sensitive towards the chlorinated than the free compounds. The sensitivity of elec- tron capture detection of the halo-acetates was highly increased as compared with&e sensitivity of flame and argon ionization detection of the free and halo-acetylated compounds, Whereas chXoroacetates in general proved to be more sensitlva for electron capture d&e&ion than bromo- and fluoro-acetates, the detection of monoch~oroacetate~proved to be more sensiti- ve than detection of the dichloro- and trichloro-acetates, We have been able to confirm this finding in the series of chlo- roaoetates6'.